West Pharmaceutical Services, Inc.
WSTWest Pharmaceutical Services, Inc. is a global leader in providing advanced specialized healthcare packaging and delivery systems. The company focuses on innovative containment and delivery solutions for injectable drugs, including drug containers, aseptic systems, and diagnostic components, serving the pharmaceutical and biotechnology industries worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 6, 2026 | $0.22 | 2026-04-29 | 2026-04-29 |
| February 4, 2026 | $0.22 | 2026-01-28 | 2026-01-28 |
| November 19, 2025 | $0.22 | 2025-11-12 | 2025-11-12 |
| August 6, 2025 | $0.21 | 2025-07-30 | 2025-07-30 |
| May 7, 2025 | $0.21 | 2025-04-30 | 2025-04-30 |
Dividends Summary
- Consistent Payer: West Pharmaceutical Services, Inc. has rewarded shareholders with 90 dividend payments over the past 22 years.
- Total Returned Value: Investors who held WST shares during this period received a total of $14.13 per share in dividend income.
- Latest Payout: The most recent dividend of $0.22/share was paid 73 days ago, on May 6, 2026.
- Yield & Schedule: WST currently pays dividends quarterly with an annual yield of 0.24%.
- Dividend Growth: Since 2004, the dividend payout has grown by 4.8%, from $0.21 to $0.22.
- Dividend Reliability: WST has maintained or increased its dividend for 51 consecutive payments.
Company News
The Gates Foundation Trust has completely divested from Microsoft after decades of slowly selling its position. The $31.6 billion endowment has instead added West Pharmaceutical Services (WST) to its portfolio, a healthcare stock with 32 consecutive years of dividend increases and forecasted earnings growth of 14-15% annually through 2027, positi...
President Trump purchased up to $680,000 in Eli Lilly shares and $250,000-$500,000 in West Pharmaceutical shares in early 2026, with purchases coinciding with new Medicare policies favoring GLP-1 obesity drugs. Eli Lilly was selected for a CMS pilot program offering GLP-1 drugs at $50/month. The Trump Organization stated investments are independe...
West Pharmaceutical Services disclosed a material cyberattack on May 7 where unauthorized parties exfiltrated data and encrypted systems. The company has restored core enterprise systems and resumed some operations, but the full scope of damage and financial impact remain unknown. William Blair maintains an Outperform rating despite near-term unc...
The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partne...
West Pharmaceutical reported strong Q1 2026 results with adjusted EPS of $2.13 (beating consensus of $1.68) and net sales of $844.90 million, up 21% year-over-year. The company raised its full-year 2026 guidance for both revenue and EPS, driven by robust demand for GLP-1 injectable components which contributed 10% of total sales. The board also a...
